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Introduction
Trisomy 13 and 18 are genetic syndromes associated with severe
systemic anomalies. Despite recent increased survival for these
infants, little is known about the hepatobiliary complications that
may arise for them. Direct hyperbilirubinemia (DH) affects
around 1 in 2,500 (0.04%) of infants. Although it has not been
previously documented in the literature, we have clinically
perceived a high rate of DH in the infants with trisomy 13 and 18
that we have cared for at Children’s Hospital.
The goal of this study was to investigate the incidence of DH
and evaluate structural and biochemical signs that could suggest
possible underlying etiologies of DH in infants with trisomy 13
and 18.

Table 1. Demographics and Laboratory Values of infants with trisomy 13 and 18

Gestational age at birth (wks)
Birth weight (g)
Male sex
Race/Ethnicity
White
African American
Other
DH
Defined as >1 mg/dL
Defined as >2 mg/dL
Median peak AST
Median peak ALT
Median peak GGT

Trisomy 13
(n=13)
37 (35, 38)
2620 (2048, 2685)
5 (38.5)
7 (53.8)
5 (38.5)
1 (7.7)
7 (53.8)
7 (53.8)
112 (70, 158)
32 (29, 122)
114 (37, 241)

Trisomy 18
(n=22)
37 (36, 38)
2040 (1680, 2235)
4 (18.2)
20 (91.0)
0 (0.0)
1 (4.5)
9 (40.9)
5 (22.7)
196 (90, 282)
75.5 (38, 168)
633 (282,1089)

Continuous variables described as median (IQR) and categorical as N (%)
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Methods
• Retrospective cohort study
• Inclusion:
• Born between January 1, 2012 and March 1, 2020,
• Diagnosed with trisomy 13 or 18, and
• Admitted to the CHMC or NMC NICUs
• Exclusion:
• Admitted after the first month of life
• Had fewer than three bilirubin data points recorded
• DH cutoffs of >1 mg/dL as well as >2 mg/dL were used
• Data collected:
• Demographics (sex, GA, race, birth weight, cardiac dx)
• Labs (direct/indirect bilirubin, GGT, AST, ALT)
• Nutrition (TPN type and duration)
• Treatment (ursodiol, phenobarbital)
• Hepatobiliary imaging (ultrasound)
• Analyses between trisomy 13 and 18:
• Descriptive analyses of bilirubin levels
• Continuous variables compared using Fisher’s exact test
• Mann-Whitney U test was used for comparing categorical
variables

Results
● Rates of DH were high in patients with trisomy 13 or 18 with a trend
toward higher rates in trisomy 13 (Table 1) when using the cutoff of
>1 mg/dL (p=0.503) or >2 mg/dL (p=0.079)

● Indirect and direct bilirubin levels are described in Fig. 1
● There was no association between DH and race (white vs. African
American, p=0.999), sex (p=0.361), BW (p=0.444), GA (p=0.463).

● There were higher rates of DH in those infants who received TPN
compared to no TPN (50.0% vs. 13.3%, p=0.026).

● Overall rates of DH were still high, however, in those without TPN
(15% for >2 mg/dL and 20% for >1 mg/dL)

● Of those that presented in the first week, 5/7 (71.4%) had trisomy
13, and infants with trisomy 13 tended to present earlier than those
with trisomy 18 (median 5 vs. 12 days, respectively, p=0.097).

● There was no difference in the rate of abnormal hepatobiliary
ultrasound between infants with and without DH (p=1.00).

Conclusion
● DH was more common with Trisomy 13 and 18 patients than what
has previously been reported for the general population
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● This remained true even when excluding those that received TPN
● Clinicians should consider screening all infants with trisomy 13 and
18 for DH starting in the first week of life and for 4 weeks or until
cessation of TPN, whichever comes later

● Future studies should focus on etiology of DH in each of these
chromosomal abnormalities individually

Figure 1. Indirect (A) and direct (B) bilirubin by day of life and direct bilirubin
stratified by trisomy 13 (C) and 18 (D). The dashed line in B represents the cutoff
of 1 mg/dL. Each line in C & D represents a single subject’s trend.
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